MESI published a Danish nationwide study following over 4.2 million people aged 40 to 99, identifying 151,846 symptomatic peripheral arterial disease diagnoses.
Public source
Publisher name
Public post
More than 1 in 10 people may be diagnosed with symptomatic peripheral arterial disease during their lifetime. A Danish nationwide study followed more than 4.2 million pe…
Company
MESI
Integrated Diagnostics. Simplified care.
- Industry
- Medical Equipment Manufacturing
- Location
- Četrtna skupnost Dravlje, SI
- Company size
- 201–500 employees
About MESI
We are an innovative company with headquarters in Slovenia and subsidiaries in several EU countries. We develop and manufacture medical devices for diagnostic purposes. Our solutions are suitable for all medical environments, from private practices to hospitals and home care. Our mission: We simplify patient assessment with integrated diagnostics, empowering healthcare professionals to detect and manage conditions and diseases better.
See moreLatest activity
Latest activity from MESI
6 signals
Presence & Recognition
MESI Conference 2026 featured a short interview and full article by Professor Rosa Maria Bruno, MD, PhD, discussing arterial stiffness, vascular ageing, and personalised prevention.
Presence & Recognition
MESI participated in the PAD Awareness Month event in September.
Presence & Recognition
MESI was recognized among Future 100 Slovenia presented by IEDC - Bled School of Management at Bled Strategic Forum.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Solaris Endovascular
Solaris Endovascular announced 92.7% target lesion primary patency at six months with investigational Solaris DE in the DEScover Phase II study presented at CIRSE 2026.
Research & Knowledge
medi UK
medi UK has launched a national research study exploring the experiences of people living with varicose veins or venous leg ulcers in partnership with the University of Wales and Medtronic.
Research & Knowledge
iVascular
iVascular presented new 3-year data at CIRSE 2026 showing Luminor DCB in femoropopliteal lesions has 88.3% fTLR safety and efficacy with sustained clinical benefit over time.
Research & Knowledge
Shockwave Medical
Shockwave Medical published a Vascular News supplement examining the evolving role of Shockwave IVL in the treatment of complex calcified lesions, highlighting calcium modification and endovascular intervention in peripheral lesions.
Research & Knowledge
Argon Medical Devices, Inc.